CLL1 Single-Domain Antibodies, Legend Biotech, Apr 2026
Summary
The European Patent Office published patent application EP3850013A1 for Legend Biotech Ireland Limited and Legend Biotech USA Inc., covering single-domain antibodies against CLL1 (C-type lectin-like molecule-1) and therapeutic constructs thereof. The application claims priority from earlier filings and specifies use in treating hematologic malignancies. The patent designates all relevant European member states as covered jurisdictions.
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 46 changes logged to date.
What changed
The EPO published patent application EP3850013A1 for single-domain antibodies against CLL1 and constructs thereof. The applicants, Legend Biotech Ireland Limited and Legend Biotech USA Inc., seek protection for antibody compositions and methods of treating conditions expressing CLL1. Designated states cover all major European jurisdictions including DE, FR, GB, NL, and others.
For biotechnology firms developing cancer immunotherapies, this patent establishes intellectual property around CLL1-targeted single-domain antibody formats. Companies working on AML (acute myeloid leukemia) therapeutics or CAR-T cell constructs using CLL1 as a target should review Freedom to Operate implications in European markets.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SINGLE-DOMAIN ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
Publication EP3850013A1 Kind: A1 Apr 15, 2026
Applicants
Legend Biotech Ireland Limited, Legend Biotech USA Inc.
Inventors
ZHANG, Wang, LIU, Yunlei, TU, Xiaojie, SHU, Chenyu, ZHAN, Tailan, ZHANG, Yun, TANG, An, ZHANG, Yafeng, WU, Shu, ZHANG, Qing
IPC Classifications
A61K 39/395 20060101AFI20220829BHEP A61P 35/00 20060101ALI20220829BHEP C07K 16/28 20060101ALI20220829BHEP C07K 19/00 20060101ALI20220829BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.